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Abstract
PDZ (PSD95/Discs large/ZO-1) domains are ubiquitous protein interaction motifs found in
scaffolding proteins involved in signal transduction. Despite the fact that many PDZs show a
limited tendency to undergo structural change, the PDZ family has been associated with long-
range communication and allostery. One of the PDZ domains studied most in terms of structure
and biophysical properties is the second PDZ (“PDZ2”) domain from protein tyrosine phophatase
1E (PTP1E, also known as PTPL1). Previously we showed through NMR relaxation studies that
binding of the RA-GEF2 C-terminal peptide substrate results in long-range propagation of side-
chain dynamic changes in human PDZ2 [Fuentes, et al., J. Mol. Biol. (2004), 335, 1105-1115].
Here, we present the first X-ray crystal structures of PDZ2 in the absence and presence of RA-
GEF2 ligand, solved to resolutions of 1.65 and 1.3 Å, respectively. These structures deviate
somewhat from previously determined NMR structures, and indicate that very minor structural
changes in PDZ2 accompany peptide binding. NMR residual dipolar couplings confirm the crystal
structures to be accurate models of the time-averaged atomic coordinates of PDZ2. The impact on
side-chain dynamics was further tested with a C-terminal peptide from APC, which showed near-
identical results to that of RA-GEF2. Thus, allosteric transmission in PDZ2 induced by peptide
binding is conveyed purely and robustly by dynamics. 15N relaxation dispersion measurements did
not detect appreciable populations of a kinetic structural intermediate. Collectively, for ligand
binding to PDZ2, these data support a lock-and-key binding model from a structural perspective
and an allosteric model from a dynamical perspective, which together suggest a complex energy
landscape for functional transitions within the ensemble.
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The PDZ (PSD95/Discs large/ZO-1) domain family is one of the most abundant protein
interacting modules found from bacteria to humans, with over 200 PDZ domains encoded in
the human genome (1-3). While they influence diverse functions in the cell, they are
typically involved in targeting and assembly of multiprotein signaling complexes at
synapses or other membrane proximal loci. PDZ domains fulfill this function through their
facility in binding C-termini sequences (4-7 amino acids) of target proteins. They are often
found in tandem arrays within a PDZ-containing protein, consistant with their role as
scaffolds for association with membrane receptors, enzymes and ion channels (1). They
share a common fold, consisting of 2 α-helices and 6 β-strands, with the second α-helix (α2)
and second β-strand (β2) forming the canonical peptide binding groove (4).
In addition to scaffolding, numerous studies indicate that PDZ domains can have more direct
regulatory functions. In particular, a subset of PDZs has now been characterized as
displaying allostery (5-10). This is exemplified by the PDZ domain from Par6, which, upon
binding CDC42 to the adjacent semi-CRIB motif contacting the PDZ at an interface away
from the peptide binding groove, undergoes a conformational change at the binding groove
(5). There is also recent evidence for interdomain allostery with PDZs (8,11-12). Thus,
while all PDZs have the capacity to serve as “passive” scaffolds, at least a subset appear to
possess higher-order functional roles (13). A central question in the PDZ field is, what
distinguishes allosteric PDZs from simple scaffold PDZs, and to what degree are allosteric
properties conserved? Further, although only some PDZs have “active” functions, are some
properties related to these functions found in all PDZs because they either derive from a
common descendent or those properties are intrinsic to the PDZ fold? Interestingly, although
many PDZ structures have been determined in the absence and presence of ligands,
observations of large conformational changes in PDZ domains have been rare (14). Thus,
much of the exploration of potential allosteric effects in PDZs have focused on more subtle
origins than gross conformational change (see below).
As a result of such questions, during the last decade PDZ domains have been selected for
biophysical study of their internal signaling properties. In 1999, Ranganathan and coworkers
used sequence covariation analysis to reveal an evolutionarily conserved energy
transmission pathway that connected to a key residue in the peptide binding site (15).
Specific PDZ domains were subsequently tested for intramolecular energy propagation
using perturbation-response approaches (16-18), and analogous computational methods were
developed that revealed PDZ-specific communication pathways (19-23). These studies
demonstrated that perturbation at localized positions in PDZ domains cause changes in
dynamic fluctuations that propagate to more distal regions of the domain. They also have
typically focused on two specific PDZ domains: PDZ3 from postsynaptic density-95
(PSD-95), and PDZ2 from the protein tyrosine phosphatase PTP1E/PTPL1. Hence, “PDZ3”
and “PDZ2” have emerged as the preferred PDZ domains for biophysical studies. Because
of their representative status, gaining complete structural, dynamic, and biochemical
information on these systems is highly desirable for fundamental understanding of PDZ
domain function.
Historically, long-range effects (e.g. allostery) have been associated with conformational
change. Thus, to understand how certain PDZ domains carry out their active functions, it is
necessary to evaluate both structural and dynamic features of these systems. The archetypal
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PDZ domain is the third PDZ domain (“PDZ3”) from PSD-95. Early structural studies
demonstrated a lack of significant structural change upon binding C-terminal peptide ligand
(24). Recently, Petit et al. showed that PDZ3 is indeed allosteric and that the mechanism of
allostery is not structural, but resides in the conformational entropy of side-chain dynamics
(9,25). In the case of PDZ2 (second PDZ from PTP1E/PTPL1, human form), the issue of
structural change upon ligand binding is less clear. Several NMR structures have been
reported for PDZ2. Human PDZ2 was reported for the apo state (26) and bound to RA-
GEF2 peptide (27). Although the backbone RMSD (using mean structures) between these
two structures is 1.3 Å, with some subtle shifting of α2 upon peptide binding, clear
conformational changes were not mentioned (27). Mouse PDZ2, which differs by 6 amino
acid substitutions (mostly in loops), was reported for the apo state (28) and bound to the
APC peptide (18). Subtle but significant structural changes were found upon APC binding,
with a change in the tilt of α2 of 10° (18). One complication in interpreting these NMR
structures is that the free mouse and human do not agree very well and there appear to be
some statistical problems with human PDZ2, as pointed out (28). In addition, none of these
structures agree well with residual dipolar coupling (RDC) measurements reported here.
Thus, at least for human PDZ2 binding the RA-GEF2 peptide, the question of
conformational change has remained unresolved. As a result, in our previous study of side-
chain dynamics in PDZ2 we concluded that a substantial role of structural changes in
dynamic propagation could not be excluded (16).
In addition to the role of dynamics in intramolecular signaling in PDZ domains, dynamics
has also been proposed to be important for PDZ domains' binding promiscuity and
specificity (29-32). Specific PDZ domains can bind to different classes of peptide ligands,
and conversely, different PDZs are known in some cases to bind the same ligand (33). Still
unknown is how specific PDZ domains achieve the optimal balance between promiscuity
and specificity, an issue also important for PDZ targeted drug design (34-35). The origin of
PDZ binding promiscuity is an active area of research.
Because of the popularity of PDZ2 for structure-based biophysical studies of folding
(36-40), binding (8,18,31,39), and energy transmission (16-17,21-22,41-42), the lack of
reliable structural models for free and peptide-bound PDZ2 has compromised the
interpretations of these studies and threatens to discourage future work on this model
system. Without good structural information, it is impossible to weigh the balance of
structure and dynamics in PDZ2, and, by extension, in PDZ domains. Here, we have
determined the structural coordinates of apo and RA-GEF2 bound human PDZ2 using X-ray
crystallography to resolutions of 1.65 and 1.3 Å, respectively. The coordinates were found to
be consistent with solution NMR RDC measurements, thus indicating that the structures also
represent (time-averaged) PDZ2 faithfully in solution. Overall, changes in PDZ2 structure
upon binding RA-GEF2 peptide are very small with RMSD of 0.3 Å. In addition, to test the
robustness of our previous finding of propagation of dynamic changes in PDZ2 and to gain
insight into binding specificity, we also characterized dynamic propagation upon binding a
C-terminal peptide from APC, using 2H methyl relaxation. These results show that both RA-
GEF2 and APC peptide binding induce highly similar long-range perturbative effects to ps-
ns side-chain dynamics, and this propagation is not driven by structural changes. Finally, to
gain insight into the mechanism of peptide binding, both RA-GEF2 and APC peptides were
investigated for their binding kinetics at the site-specific level using NMR relaxation
dispersion methods.
Zhang et al. Page 3














Protein expression and purification
The second PDZ domain (1361-1456) from human PTP1E/PTPL1 was sub-cloned into
pET21 vector as described (16). Protein was overexpressed in the BL21(DE3) cell line in
LB or M9 minimal media. Cells transformed with PDZ2 vector were induced with 1 mM
IPTG and grown at either 22 or 37 °C overnight for protein expression. PDZ2 was purified
using the same procedure as reported (16) and verified by mass spectroscopy. For
crystallization, protein was exchanged into buffer containing 50 mM NaCl and 20 mM Tris-
HCl pH 6.8. For NMR study, protein was dissolved in 150 mM NaCl and 50 mM sodium
phosphate pH 6.8, and 10% D2O. To prepare isotope-labeled samples for NMR, isotopically
enriched chemicals (15NH4Cl, U-13C6 (99%) D-glucose, and D2O) were used in the minimal
media.
Peptide preparation
RA-GEF2 peptide (Ac-ENEQVSAV) was a product of GenScript (Piscataway, NJ). The
peptide concentrations were determined by PULCON (43-44). APC peptide (GSYLVTSV)
was chemically synthesized with F-MOC modified amino acids using solid phase methods
(45). The peptide product was purified by HPLC using a reversed-phase C18 column and
acetonitrile gradient. The identity and purity of the resultant peptide was checked by mass
spectrometry. The APC peptide stock concentration was determined by UV absorbance with
an extinction coefficient of 1490 cm−1M−1 at 280 nm.
Crystallization
The apo and RA-GEF2 bound PDZ2 crystals were obtained using the hanging drop diffusion
method. Apo-PDZ2 was crystallized via mixing 1.5 μl of 60 mg/ml protein and 1.5 μl of
well buffer containing 28% PEG 3350, 0.2 M KI, 0.2 M NaSCN, 0.1 M sodium acetic acid
pH 4.5, and 5% 2-propanol at room temperature. RA-GEF2 bound PDZ2 co-crystals were
obtained in 20% PEG 3350, 0.2 M NaSCN, 0.8 M (NH4)2SO4 and 0.1 M sodium citrate pH
5.5 in the presence of 10 mM RA-GEF2 peptide at 4 °C. It should be noted that these
crystallization solutions served as effective cryoprotectants. In the case of the complex,
incomplete mixing of PEG and (NH4)2SO4 likely led to high local concentrations of PEG.
Therefore, the crystals of free and peptide-bound PDZ2 were directly flash-frozen using
liquid nitrogen for storage without additional cryo protection step.
Structure determination and refinement
The apo and peptide bound PDZ2 domain crystal diffraction data were collected in beamline
X29A of the National Synchrotron Light Source at Brookhaven National Laboratory. Both
data sets were collected with X-ray wavelength 1.0809 Å at 100 K (Table 1). Space groups
were determined using xtriage (46). The integrated and scaled data by HKL2000 (47) were
applied to AMoRe integrated in the CCP4 package for molecular replacement (48). To build
the initial apo structural model, PDZ2 from SAP97 (49) (PDB ID: 2AWX) was used as a
search model. The apo structure was processed further with alternating rounds of refinement
by REFMAC (50) and phenix.refine (51) and manual model building by Coot (52). TLS
refinement with phenix was applied with TLS parameters from the TLSMD server (53).
Densities for the iodine ions, which were added during the crystallization process, were
characterized utilizing Bijvoet difference maps. For the peptide-bound structure model, the
apo PDZ structure was utilized as a search model for molecular replacement, but without
peptide coordinates to rule out phase bias. Peptide electron density was clearly visible after
the first cycle of refinement and then filled with peptide model. The peptide-bound structure
was also processed with alternating rounds of refinement by REFMAC (50) and
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phenix.refine (51) and manual model building by Coot (52). During refinement with
phenix.refine, the individual anisotropic ADP refinement option was utilized. Both
structures have weak additional electron densities occupying the non-protein space that are
modeled with water molecules.
NMR spectroscopy
All NMR experiments were carried out at 25 °C (calibrated using methanol) on 500 and/or
600 MHz Varian Inova spectrometers. The protein concentration used was 1 mM. To
prepare peptide saturated protein samples, RA-GEF2 or APC peptide was added to a
peptide:protein ratio of 1.8:1. Protein concentrations were determined by UV absorbance
with ε280=1490 cm−1M−1. All NMR spectra were initially processed by NMRPipe (54) and
subsequently applied to NMRView (55) or in-house programs lab for further analysis.
RDC data collection and analysis
Using the IPAP-HSQC experiment (56), 15N-1H RDC data were collected for isotropic and
anisotropic samples on a 500-MHz magnet. Proteins were aligned by axial stretching of a 6-
mm polyacrylamide gel (6%) into a 5-mm NMR tube (New Era Enterprises, Inc., Vineland,
NJ) (57). The residual dipolar couplings were extracted using the RDC module of
NMRPipe. Q-factors of RDC data were calculated by REDCAT (58). The residues in
flexible loops, termini together with overlapping resonances were excluded in RDC data
analysis.
Binding affinities and populations
The binding affinity between the RA-GEF2 peptide and PDZ2 was determined by
fluorescence and further confirmed by NMR titration. The two methods produced the same
Kd of 10 μM. The APC-PDZ2 binding affinity was also measured by NMR titration,
yielding a Kd of 10 μM (Fig. S3). With Kd, [peptide], and [PDZ2] known, the populations of




where [PB] is the peptide-bound PDZ2 population and [PA] is the unbound PDZ2
populations.
15N Relaxation dispersion
15N Carr-Purcell-Meiboom-Gill (CPMG) relaxation dispersion experiments were carried out
using compensated CPMG pulse sequence (59). For all PDZ-peptide complexes, time delays
between consecutive 180° CPMG pulses were set as 0.556, 0.652, 0.75, 0.936, 1.25, 1.5,
1.875, 2.5, 3, 3.75, 5, 7.5, and 15 ms. The total relaxation time in CPMG train was 60 ms.
The RA-GEF2 bound PDZ2 relaxation dispersion data were acquired at two sub-saturated
states with peptide:protein molar ratios of 1:19.6 and 1:1.97, respectively. APC bound
relaxation dispersion data were collected at a single peptide:protein ratio of 1:19.6. The
relaxation dispersion data were collected on 500 and 600 MHz spectrometers in an
interleaved manner.
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Relaxation dispersion curves were fitted both locally (residue-specific fits) and globally
using the in-house program exrate (60). For global fitting, a single exchange rate kex, a
single [PA], and residue-dependent Δω and R20 values were fitted using the general Carver-
Richards expression (61). For the sample with ∼5% saturation, [PA] obtained from global
fitting was 94.7%, in excellent agreement with 94.8% based on known Kd and
concentrations. We found that fitted Δωs agreed very well with the directly observed
chemical shift differences between free and fully saturated PDZ2 (Δωtitration). For local
fitting of individual residues, the [PA] [PB] product was set as a known constant (based on
the global fit). In the local fits, the better of the two fits between use of the general or “fast”
models was determined based on agreement of ΔωCPMG with Δωtitration.
ps-ns dynamics
Backbone and side-chain dynamics of APC-bound PDZ2 was studied in the same manner as
for the RA-GEF2 complex reported previously (16). Briefly, 15N backbone relaxation
experiments were used to collect 15N T1, T2 and {1H}-15N nuclear Overhauser enhancement
(NOE) (62) at 500 MHz and 600 MHz. Methyl bearing side-chain dynamics was extracted
from 2H relaxation within CH2D isotopomers. IzCz, IzCzDz and IzCzDy relaxation
experiments were collected at 500 and 600 MHz and analyzed as described previously (16).
Results and Discussion
Crystal structures of apo and peptide-bound PDZ2
In order to detect conformational changes resulting from peptide binding, crystallography
was employed to determine structures of PDZ2 in the absence and presence of an 8-mer C-
terminal peptide ligand from RA-GEF2 (27,63). Crystals in both forms diffracted X-rays to
reasonably high resolution, 1.65 Å for apo PDZ2 and 1.3 Å for RA-GEF2 bound PDZ2,
respectively. The final R-factors for apo and peptide-bound PDZ2 are 19.7% and 16.4%
respectively (Table 2).
Apo PDZ2 crystals belong to the P212121 space group. In the asymmetric unit, six
monomers are packed to form two layers of three-blade propeller like structures (supporting
materials, Fig. S1A and S1B). The average pair-wise Cα RMSD of the monomers is 0.18 Å,
indicating all monomers are essentially identical. As expected, the crystal structure solved
here conforms to the canonical PDZ domain fold, comprising 6 β-strands and 2 α-helices
(Fig. 1A). The second β-strand (β2) and the second α-helix (α2) constitute the peptide
binding groove. The RA-GEF2:PDZ2 complex crystals belong to space group R32 (H32).
One molecule appears in each asymmetric unit. A hexamer conformation (32 symmetry),
generated by crystallographic symmetry, is identical to the hexamer structure in the apo
form. Based on calculation of the buried surface area in the hexamer interface by PISA (64),
this PDZ domain molecule is expected to exist as a hexamer in solution; however, there is
no evidence of this from NMR relaxation (16), which is sensitive to the rate of molecular
tumbling, nor are higher-order oligomeric species evident from size exclusion
chromatography. In the peptide-bound PDZ2 structure (Fig. 1B), hydrogen atoms were also
modeled. In the RA-GEF2 peptide, the five C-terminal residues (QVSAV) show electron
density. Using PDZ ligand numbering, counting backwards from the C-terminus, these are
residues (0) to (−4). The RA-GEF2 peptide fitted into the binding groove forms an anti-
parallel β-strand with protein strand β2. The interaction is further strengthened by packing of
the most C-terminal valine side chain with the surrounding hydrophobic patch. The
interaction is also stabilized by hydrogen bonding between Ser(−2) and the conserved H71
sidechain, as well as between the backbone of Ala(−1) and R79. In the apo state, the side
chain of R79 adopts different conformations in the six different monomers. Upon binding
peptide, this apparent flexibility is lost by hydrogen bonding to the carbonyl of Ala(−1).
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Consistent with previous studies, RA-GEF2 residues back to (−4) are hydrogen bonded with
the protein (Fig. 1C) (26). In establishing this intricate hydrogen bonding network, several
bound water molecules are also involved (Fig. 1C).
All atoms of apo and bound structures have very distinct electron densities, except side-
chain atoms of loop residues S29-G33 and terminal residues Q93 and S94. Intriguingly, an
irregular 310-helix is identified for residue fragment 30-33 (VRHGG), which is usually
characterized as a partially structured loop in NMR structures or other PDZ2 homologues.
Compared to the average temperature factor of the free protein (38 Å2), high temperature
factors (68 Å2 on average) are observed for this fragment, suggesting high flexibility. Even
though B-factors are high, the backbone traces are very similar for all PDZ molecules. This
fragment is also involved in crystal packing for both apo and peptide-bound PDZ2, as
revealed by crystal lattice packing (Fig. S2). It is thus possible that the 310-helix of residues
30-34 is stabilized in part by the crystal lattice. Nevertheless, in PDZ domains from HtrA
proteases, non-canonical helices have been observed in the intervening residues between β2
and β3 (65). Furthermore, 13Cα chemical shifts are consistent with some degree of helicity in
solution for residues 31-33 (in both free and RA-GEF2 bound states), with an average
(positive) deviation from random coil values of 1.6 ± 0.4 ppm.
These high-resolution structures enable a new assessment of ligand induced conformational
changes in PDZ2. As shown in Fig. 1D, no substantial conformational changes are observed:
the Cα RMSD of apo and peptide-bound structures is 0.29 Å (0.21 Å if loop residues 26-32
are excluded). This is reminiscent of peptide binding to PDZ3 of PSD95, for which no
structural change was found (24), but distinct from the previously published NMR model of
APC-bound mouse PDZ2, for which a 10° rotation of α2 was reported (18). The differences
between the crystal structures and previously published PTP1E PDZ2 NMR structures are
compared quantitatively in Table 3. The RMSDs between crystal and NMR structures range
from 0.9 – 2.0 Å. Upon superposition of the apo and bound crystal structures here
(excluding α2), RA-GEF2 binding induces a reorientation of α2 of only 2.8°. Thus, based on
RMSDs, our crystal structures appear very similar to each other, yet show significant
differences from the other PDZ structures. Significant discrepancies are also found among
the NMR structures (Table 3), which are either human or mouse forms, even though human
PDZ2 (3PDZ and 1D5G) (26,28) differs from mouse homologue (1GM1 and 1VJ6) (18,27)
by only 6 residues (including 2 conservative mutations). One possible source for these
discrepancies is the different methodologies in structure determination. Despite the apparent
high resolution, the crystal structures may be influenced by crystal packing effects that
introduce structural artifacts and conformational trapping (66-67). Similarly, the NMR
structures may suffer from inadequate NOE's to fully define the structure in all regions. Thus
a question arises: Are the crystal structures solved here good models for PDZ2 in solution?
This prompted us to employ a solution-based approach, residual dipolar couplings (RDC), to
further assess the crystal structures.
Structure validation through solution RDCs
Residual dipolar couplings (RDCs) provide orientation information on internuclear vectors
in biomolecules and are widely used in NMR structure calculations and domain-domain
docking (68). Alternatively, solution RDCs can be used as a powerful tool to assess the
quality of structural models generated without RDC information, which includes, for
example, crystal structures. Similar to the R-factor in crystallography, a quality metric called
the Q-factor is calculated by fitting experimental RDC data to a structural model (69). The
Q-factor varies between 0 and 1, with low Q values indicating high consistency between
RDCs and the model, and high values indicating low consistency. Thus, high Q values (>
0.3-0.4) are generally suggestive of low structural quality, assuming that there are no
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problems/artifacts in the RDCs. Due to intrinsic errors in RDC data collection, the lower
limit for Q-factors in practice is around 0.1 (70).
To evaluate all deposited PDZ2 structures (none of which used RDCs in refinement),
amide 1H-15N RDC data were collected for PDZ2 in apo, RA-GEF2 bound, and APC bound
states. The crystal structures of apo and RA-GEF2 bound forms fitted to their respective
RDCs yield low Q values of 0.22 and 0.21 respectively (Table 4). This good agreement
suggests that the crystalline PDZ2 structures are not significantly affected by crystal packing
and conformational trapping. By contrast, the NMR structures generate significantly higher
Q values (from 0.39 to 0.82, Table 4). We note that many of the RDCs were also collected
using lipid bicelles, and the Q-factors were very similar (data not shown). Overall, based on
the computed Q-factors, the crystal structures reported here represent the average solution
features of PDZ2 (apo or bound) significantly better than the existing NMR structures. We
therefore expect that these crystal structures will provide more accurate coordinates for
molecular dynamics simulation starting structures or structure-based studies of PDZ2.
In addition, the RDC analysis suggests that an overall lack of change in the time-averaged
conformations of PDZ2 in response to peptide binding also holds true in solution. This is
evident from the low Q-factors of 0.22 and 0.21 for apo and bound PDZ2 (Table 4). It is also
evident upon considering that the apo PDZ2 RDCs are nearly as consistent with
PDZ2RA-GEF2 structure as with apo PDZ2 (Q-factors of 0.29 versus 0.22). Conversely, the
PDZ2RA-GEF2 RDCs are nearly as consistent with the apo structure as with the
PDZ2RA-GEF2 structure (Q-factors of 0.26 versus 0.21). These relatively small differences in
Q-factors (0.05, 0.07) are suggestive of subtle structural and/or dynamic differences that
exist between free and RA-GEF2 bound forms, although a significant portion of the
differences may be due to experimental uncertainty in the RDCs. It is interesting to note that
RDCs from the APC-PDZ2 complex fit slightly better to apo-PDZ2 than the RA-GEF2
bound structure (Table 4). We note that the Q-factor fitting included RDCs from α2 and β2
(Fig. S4), which form critical hydrogen bonds with peptide and should report on any
structural change. The RDC data here appear to contradict a previous report of a 10° change
in α2 orientation, in solution, upon binding the APC peptide (18). However, that was carried
out on mouse PDZ2, and it remains possible that mouse and human PDZ2s differ in this
respect. We also note that there may be dynamic aspects to α2 in human PDZ2, as suggested
from a slightly increased 15N R2 at R79 relative to the other structured regions (in the apo
form, data not shown). We speculate that α2 may undergo segmental motion on the ns-μs
timescale. In summary, the RDC data are highly consistent with the crystal structures and
show that neither RA-GEF2 nor APC peptides induce significant conformational changes to
human PDZ2 in solution.
Long-range “pure” dynamic propagation in PDZ2 also results from APC peptide binding
In our previous study of the RA-GEF2 peptide binding to PDZ2 (16), binding was observed
to perturb ps-ns dynamics of methyl-bearing side chains not only at the binding site, but also
at two surfaces of PDZ2 distal to the peptide binding pocket. At that time, it was unclear to
what extent the dynamic propagation was due to changes in peptide-induced structural
changes in PDZ2. The combined crystallographic and NMR results here strongly suggest
that conformational change does not drive the dynamic changes and that PDZ2 channels the
impact of peptide binding as a relatively “pure” dynamic response to distal surfaces 1 and 2
(16). The emerging picture appears to be that a network of residues extends through much of
PDZ2. Atom fluctuations around mean positions of the network confer variable force
patterns that can transmit perturbations over distances. We note that such behavior has
recently been used as a perturbation-response tool in the context of molecular dynamics
simulations (20-21,71-72). Thus, a major event such as peptide binding in the PDZ active
site can alter fluctuation patterns well beyond the binding site without significant changes in
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mean structural positions. The patterns may in some cases manifest as correlated motions, as
demonstrated recently for PDZ2 (42). This qualitative model is consistent with the ease of
dynamic perturbation by both mutation and ligand binding (73).
To further test this model and potentially increase confidence in the long-range dynamic
propagation observed for RA-GEF2 binding, we characterized the methyl side-chain
dynamics of PDZ2 bound to a C-terminal peptide derived from the APC protein (74)
using 2H relaxation. This peptide (GSYLVTSV) binds with Kd ∼10 μM, similar to RA-
GEF2 (Fig. S3). The changes in S2axis and τe upon APC peptide binding are very similar to
those in RA-GEF2 (Fig. 2 for S2axis and Fig. S5 for τe). The patterns of changes in S2axis in
PDZ2 upon binding either peptide are shown in Fig. 3. In the case of RA-GEF2 binding,
propagation was previously observed out to “distal surfaces 1 and 2”, although distal surface
1 is less apparent in Fig. 3A because changes in τe are not shown. In the APC complex, only
propagation to distal surface 1 is observed, but the pattern is near identical to that from RA-
GEF2, both in terms of residues in the dynamic network and the magnitude of the dynamic
response. One residue that shows a different response from the RA-GEF2 complex is at I6 at
the N-terminal region of beta strand 1. Construction of a 2-way contingency table based on
the presence or absence of significant ΔS2axis values in specific methyl groups in both
complexes resulted in a high level of pattern matching, with the Fisher's exact test p-value of
7.4 × 10-4 (Table 5). This high degree of similarity in dynamic responses to RA-GEF2 and
APC peptides demonstrates that the propagated dynamic responses are indeed real,
reproducible, and more indicative of PDZ2 than ligand sequence (at least in these two
cases). In addition, because the 1H-15N RDCs measured for APC-bound PDZ2 agree equally
well with the crystal structure of RA-GEF2/PDZ2 (Q = 0.23, Table 4), these data also
support pure dynamic propagation. We suggest that these data represent one of the best
examples of dynamic propagation – or dynamic signal transduction (75) – detected
experimentally and site-specifically, in the absence of conformational changes (25,76-77).
μs-ms timescale peptide binding dynamics
A previous pre-steady state kinetic study of mouse PDZ2 binding to RA-GEF2 peptide
showed that peptide association proceeds through an induced-fit mechanism (18). These
kinetic data suggested that PDZ2 undergoes a ligand induced conformational change with
kobs of ∼7000 s−1. While the X-ray and RDC data presented above (on human PDZ2) do not
support the existence of overall conformational change, it remains possible that
conformational changes take place at low populations. To probe this possibility, we
investigated μs-ms motions in PDZ2 using Carr-Purcell-Meiboom-Gill (CPMG) relaxation
dispersion methods (61). In principle, this strategy allows monitoring of the kinetics (kex)
and structural effects (as interpreted through the difference in chemical shift between states,
Δω) of conformational events at the residue level and can detect minor populations as low as
0.5-1% (78).
Microsecond-millisecond timescale dynamics are frequently associated with conformational
change, enzyme catalysis, and protein folding (79). 15N CPMG relaxation dispersion
experiments revealed that neither apo PDZ2 nor RA-GEF2 saturated PDZ2 exhibit
significant μs-ms motion (data not shown). However, for binding interactions of moderate
strength (∼micromolar), ligand binding and dissociation can occur on this timescale and are
amenable to characterization by relaxation dispersion using sub-saturated complexes
(80-83). More specifically, there is the potential for identification of dynamic events that
occur during binding. Of interest here, non-two-state behavior was reported recently for
peptide binding to the PDZ domain of AF-6, based on relaxation dispersion data (84). To
gain insight into the kinetics of binding and ligand specificity with site-specific resolution
for PDZ2, 15N CPMG relaxation dispersion experiments were carried out on both RA-GEF2
and APC peptide complexes with 5% or 50% molar amounts of peptide. The lack of μs-ms
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exchange in the end states of the binding reaction is ideal for interpretation of line-
broadening (i.e. relaxation dispersion) due to dynamic cycling of ligand binding and release.
To bring the peptide binding kinetics into an exchange window suitable for characterization
by CPMG relaxation dispersion, PDZ2 protein was mixed with substoichiometric amounts
of peptide. For dispersion curve analysis, we employed two-site exchange since the above
structural studies indicated no evidence for conformational change. A two-site exchange
binding process can be described by the following:
(eq. 3)
where kon and k off are the on-rate and off-rate of peptide binding, respectively. The
exchange rate (kex) is modulated by the free peptide concentration based on the following
expression:
(eq. 4)
Upon addition of 5% RA-GEF2 or APC peptide, relaxation dispersion was observed for
residues along the binding groove and some distal regions. The high quality of the fits in
Figure 4 is typical of the entire data sets for both peptide complexes. Local kex and Δω were
fit assuming a fixed pA value of 0.95. Fits were carried out using the full Carver-Richards
equation, as well as the simplified form for fast exchange (61), and we report the parameters
which yielded better agreement with Δω determined from titration. Individually fitted
exchange rates (kex), chemical shift changes (Δω) and intrinsic spin-spin relaxation rates
(R20) for PDZ2 residues in complex with RA-GEF2 and APC are provided in Tables 6 and
7, respectively. The distribution of kex values were quite uniform, with average kex values of
408 ±127 s and 663±158 s for PDZ2 bound to 5% RAGEF or 5% APC peptides,
respectively. Given the similarity of the locally fitted exchange rates, the data for each
complex were globally fit to a model in which all residues share the same exchange rate and
population, but Δω and R20 are allowed to vary for each residue. The global fitting results
are very similar to the local results (Table S1, S2). Importantly, globally fitted PA values
were determined to be 94.7% and 94.5% for RA-GEF2 and APC, respectively, in excellent
agreement with the predicted fraction of free protein (95%) based on measured Kd values
and reactant concentrations. In addition, fitted Δω values (ΔωCPMG) for both peptides are
remarkably consistent with the Δω values based on peptide titrations (Δωtitration) (Fig. 4C
and 4D). This strongly suggests PDZ2 samples two states (apo and fully bound) in the
presence of peptide and these alone are responsible for dispersion. We note however, that
there are a few resonances in each system for which we observe divergence between
ΔωCPMG and Δωtitration. In the case of the APC complex, all of these outliers have very
small Δω values. These discrepancies do not warrant further consideration since it is known
that fitting relaxation dispersion with small chemical shift changes is error prone (85). In the
case of the RA-GEF2 complex, we find Δω divergence for three residues with significant
titration Δω values: G19, S21, and G34. Interestingly, G19 and S21 exhibit the smallest
values of kex (255 and 204 s−1) in PDZ2. G19 and S21 are located at the binding pocket (in
or near β2), and G34 lies at the end of the β2-β3 loop. Thus, although the majority of
resonances in PDZ2 indicate simple two-state binding in the sensitivity regime for 15N
CPMG relaxation dispersion, these few residues appear to hint at the existence of a RA-
GEF2 binding intermediate localized to the vicinity of the peptide site. The behavior of G19,
S21, and G34 is reminiscent of previously observed non-two-state behavior in ligand
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binding as observed from NMR relaxation dispersion (80,82,86). The divergence from two-
state behavior here appears to be smaller than in those studies, yet larger than in the case of
an SH3-ligand interaction (83). Fits of the dispersion data to a 3-site exchange model was
not carried out since this is advised only for when an abundance of dispersion curves is
available (87).
The primarily two-state relaxation dispersion behavior reported here contrasts with the
CPMG-derived ligand binding dynamics in the AF-6 PDZ domain, which showed extensive
discrepancies between ΔωCPMG and Δωtitration and hence is suggestive of an intermediate
state during the binding process (84). However, in the AF-6 PDZ, the apo protein samples
different conformations on the millisecond timescale, which complicates the interpretation
of peptide binding dynamics. In the sub-saturated complexes of PDZ2, chemical exchange
only arises from peptide binding dynamics, leading to tight correlations between ΔωCPMG
and Δωtitration (Figure 4C,D). As some PDZ domains are known to change their shape
(5,14), future studies of apo dynamics and ligand binding dynamics on the μs-ms timescale
should help to determine how common alternative conformational states in PDZ domains
are.
For clean two-site exchange, it is reasonable to expect the on-rate for peptide binding (kon)
to approach the diffusion limit. To test this, we calculated kon and k off from the dependence
of kex on peptide concentration. To this end, an additional set of relaxation dispersion data
were collected with 50% RA-GEF2. The higher ligand concentration pushed exchange rates
into the intermediate regime and hence many resonances disappeared. Nevertheless, enough
relaxation dispersion curves were obtained to perform global fitting (Table 8). Solving the
two linear equations (eq. 4) at the two peptide concentrations (using globally determined
kex), the on-rate was determined to be 3.6×107 s−1 M−1, which is approaching the diffusion
limit, and the off-rate is 307 s−1, which is very similar to the previously reported value,
270±20 s-1.(18).
Summary
Taken together, the X-ray and NMR results reported here on RA-GEF2 and APC peptides
are inconsistent with an induced-fit or conformational selection mechanism of binding to
PDZ2, and highly consistent with binding via “lock-and-key”. No significant changes in
PDZ2 coordinates are observed between the apo and RA-GEF2 peptide bound crystal
structures, which is supported further by 1H-15N RDCs. The absence of significant CPMG
relaxation dispersion for apo (or peptide bound) PDZ2 is consistent with lack of
conformational change in the crystal structures. We note, however, that a caveat of the
relaxation dispersion experiments is that processes faster than ∼100 μs are not detected and
hence sampling of intermediate binding states on a timescale faster than this cannot be
excluded. In the context of this “rigid” PDZ2 domain, binding of both RA-GEF2 and APC
peptides induce very similar patterns of changes in ps-ns side-chain dynamic fluctuations
that propagate away from the binding site, forming apparent allosteric pathways. Thus, the
primary physical impact of peptide binding to PDZ2 is dynamic and not structural in nature.
This has implications for understanding the physical basis for long-range communication
and allostery in proteins.
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Abbreviations
NMR nuclear magnetic resonance
RDCs residual dipolar couplings
S2axis order parameter characterizing amplitude of methyl symmetry axis motions
PDZ PSD95/Discs large/ZO-1
APC Adenomatous Polyposis Coli-protein
RA-GEF2 Ras guanine nucleotide exchange factor 2
PTP-1E protein tyrosine phosphatase 1E
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Cartoon representation of PDZ2 crystal structures. Apo (A) and RA-GEF2 bound (B) PDZ2
structures. Peptide is shown as stick model and electron density is shown as gray mesh. The
density contour level is 1.5 σ. Peptide residues QVSAV have visible electron density. (C)
RA-GEF2 and PDZ2 interaction network. RA-GEF2 peptide is shown by stick model and
surrounding PDZ2 residues involved in peptide interaction are shown as lines. Bound water
molecules involved in PDZ2 peptide interaction are shown as blue balls. The hydrogen
bonds relevant to peptide binding are shown by yellow dotted lines. (D) Structural
Superposition of apo (magenta) and RA-GEF2 bound PDZ2 (cyan). The RAGEF peptide is
shown by green stick model. All structural graphics were prepared using PyMOL.
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Methyl-bearing side-chain dynamics changes (ΔS2axis) induced by RA-GEF2 (A) and APC
(B) binding, with respect to free PDZ2. The methyl groups with significant changes in S2axis
(ΔS2axis>2σ) are shown in filled bars. Fig 2A was adapted from Fuentes et al. (16)
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Graphical comparison of side-chain dynamic changes induced by RA-GEF2 (A) and APC
binding (B). Red spheres represent residues experiencing significant (ΔS2axis>2σ) side-chain
dynamic changes and peptide is shown as blue cartoon. The figures were prepared by
PyMOL.
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Two-state binding of RA-GEF2 and APC peptides based on 15N relaxation dispersion.
Relaxation dispersion curves for select resonances in PDZ2 5% saturated with RA-GEF2
(A) and APC (B) peptides. Data acquired at 500 and 600 MHz (1H Larmor frequency) are
shown in red and blue respectively. Data quality for these residues is typical of the entire
dataset. In (C) and (D), correlation plots of fitted Δω values from relaxation dispersion
and 15N Δω values from peptide titration. ΔωCPMG values are from global fits, as described
in the main text. Data for RA-GEF2 and APC are in (C) and (D) respectively. The line is y =
x.
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Table 1
Data Collection Statistics
Apo PDZ2a RA-GEF2 PDZ2a
Wavelength (Å) 1.0809 1.0809
Resolution Range (Å) 50-1.65 50-1.3
no. of reflections 1216653 460997
no. of unique reflections 74902 34689
Completeness (%) 98.6 (73.6)a 99.1 (97.7)
Space group P212121 H32
Cell parameters (Å) 63.023 95.148 101.989 73.965 73.965 134.056
Cell angles (deg) 90 90 90 90 90 120
Average redundancy 16.2 (10.8) 13.3 (10.7)
Rmerge (%) 11.4 (85.6)b 5.6 (18.0)
<I/σ> 19.232 47.456
a
The values in parentheses are for the highest resolution shell.
b
Rmerge = Σh Σi | Ii (h) - <I(h)>|/ΣhΣiIi(h), where Ii(h) is the intensity of an individual measurement of the reflection and <I(h)> is the mean
intensity of the reflection.
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Table 2
Structure Refinement Statistics
Apo PDZ2 RA-GEF2 PDZ2
Resolution Range (Å) 39.6-1.6 29.7-1.3
no. of reflections 133400 34191
R-factor (%)a 19.7 16.4
R-free (%)b 23.7 18.9
no. of non-H atoms 4167 1040
no. of water molecules 433 238
Ramachandranc
 In most favoured regions 98.0 98.3
 In additional allowed regions 2.0 1.7
 In disallowed regions 0.0 0.0
a
Rcryst = Σh ‖Fobs| - |Fcalc‖/Σh |Fobs|, where Fobs and Fcalc are the observed and calculated structure-factor amplitudes, respectively.
b
Rfree was calculated as Rcryst using approximately 5% of randomly selected unique reflections that were omitted from the structure refinement.
Values in parentheses are for the highest resolution shell.
c
The Ramachandran analysis is performed using Molprobity.
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Table 5




Significant 7 2 9
Insignificant 4 25 29
Total 11 27 38
The p value based on Fisher's exact test is 0.00074.
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